GRFS or SDZNY: Which Is the Better Value Stock Right Now?

In a comparison of two medical-drugs stocks, Grifols (GRFS) emerges as the superior value option over Sandoz Group AG Sponsored ADR (SDZNY). GRFS has a stronger Zacks Rank of #2 (Buy) versus SDZNY's #3 (Hold), along with significantly better valuation metrics including a forward P/E of 7.03 compared to SDZNY's 20.54, a PEG ratio of 0.28 versus 1.77, and a P/B ratio of 0.57 versus 3.95. GRFS earned a Value grade of A while SDZNY received a C.